SCHEDULE: Deerfield Funds Disclose 5.08% Stake in Inspire Medical

Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., and James E. Flynn have jointly reported a 5.08% beneficial ownership stake in Inspire Medical Systems, Inc.

Summary

• Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., and James E. Flynn (collectively, the "Reporting Persons") have filed a Schedule 13G regarding their beneficial ownership in Inspire Medical Systems, Inc.
• The Reporting Persons collectively beneficially own 1,476,303 shares of Common Stock of Inspire Medical Systems, Inc.
• This aggregate amount represents 5.08% of the outstanding Common Stock of Inspire Medical Systems, Inc.
• The Reporting Persons share both voting power and dispositive power over all 1,476,303 shares.
• The filing indicates that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a reputable healthcare-focused investment firm like Deerfield Management is generally viewed positively, indicating confidence in the issuer's long-term prospects and potentially attracting further investor attention.

Positives

• The disclosure of a significant 5.08% stake by Deerfield Management, a prominent healthcare-focused investment firm, signals institutional confidence in Inspire Medical Systems, Inc.

Negatives

• NA

Risks

• NA

Future Outlook

The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Inspire Medical Systems, Inc., nor were they acquired or held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Management Comments

• "The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of Inspire Medical Systems, Inc. shall be filed on behalf of the undersigned."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

This filing indicates continued institutional investor interest in the medical technology sector, specifically in companies like Inspire Medical Systems, Inc., which focuses on innovative solutions for sleep apnea. The investment by Deerfield Management, a specialized healthcare investor, aligns with broader trends of capital allocation towards growth-oriented healthcare firms.

Comparison to Industry Standards

• The 5.08% stake reported by Deerfield Management is a standard threshold for triggering a Schedule 13G filing, indicating a significant but passive investment in line with typical institutional portfolio allocations.
• Deerfield Management is a well-known healthcare-focused investment firm, and their investment in Inspire Medical Systems, Inc. is consistent with their established strategy of investing in medical device and biotechnology companies.

Stakeholder Impact

• Shareholders may perceive the institutional investment as a positive signal, potentially bolstering confidence in the company's stock.
• Company management will be aware of a significant passive investor on their shareholder register, which can influence investor relations strategies.

Key Dates

Recommendation

This Schedule 13G filing indicates a significant passive investment by Deerfield Management in Inspire Medical Systems, Inc. While the disclosure of a 5.08% stake by a reputable healthcare-focused firm is a positive signal of institutional confidence, it does not provide new operational or financial data that would warrant a change in investment thesis. The filing explicitly states the investment is not for control purposes. Therefore, a "hold" recommendation is appropriate, maintaining current positions based on existing fundamental analysis, with this filing serving as a supportive data point regarding institutional interest.

Keywords

Inspire Medical Systems, Deerfield Management, Schedule 13G, beneficial ownership, institutional investment, common stock, medical devices, sleep apnea